               SEQUENCE LISTING

<110> Dompé Farmaceutici SpA

<120> Peptide Endowed with Angiogenic Activity

<130> 235EPbis

<160> 18

<170> BiSSAP 1.3.6

<210> 1
<211> 20
<212> PRT
<213> Artificial Sequence


<220> 
<223> F1

<400> 1
Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu Asp Arg Trp Glu 
1               5                   10                  15      
Lys Ile Arg Leu 
            20  

<210> 2
<211> 20
<212> PRT
<213> Artificial Sequence


<220> 
<223> F2

<400> 2
Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys Lys Tyr Lys Leu Lys 
1               5                   10                  15      
His Ile Val Trp 
            20  

<210> 3
<211> 20
<212> PRT
<213> Artificial Sequence


<220> 
<223> F3

<400> 3
Lys His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Val Asn 
1               5                   10                  15      
Pro Gly Leu Leu 
            20  

<210> 4
<211> 20
<212> PRT
<213> Artificial Sequence


<220> 
<223> F4

<400> 4
Asn Pro Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Leu Gly 
1               5                   10                  15      
Gln Leu Gln Pro 
            20  

<210> 5
<211> 20
<212> PRT
<213> Artificial Sequence


<220> 
<223> F5

<400> 5
Gly Gln Leu Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser 
1               5                   10                  15      
Leu Tyr Asn Thr 
            20  

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence


<220> 
<223> F6

<400> 6
Ser Leu Tyr Asn Thr Val Ala Thr Leu Tyr Cys Val His Gln Arg Ile 
1               5                   10                  15      
Glu Ile Lys Asp 
            20  

<210> 7
<211> 20
<212> PRT
<213> Artificial Sequence


<220> 
<223> F7

<400> 7
Ile Glu Ile Lys Asp Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu 
1               5                   10                  15      
Gln Asn Lys Ser 
            20  

<210> 8
<211> 36
<212> PRT
<213> Artificial Sequence


<220> 
<223> F8

<400> 8
Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Ser Lys 
1               5                   10                  15      
Lys Lys Ala Gln Gln Ala Ala Ala Asp Thr Gly His Ser Ser Gln Val 
            20                  25                  30          
Ser Gln Asn Tyr 
        35      

<210> 9
<211> 16
<212> PRT
<213> Artificial Sequence


<220> 
<223> F3S

<400> 9
Ala Ser Arg Glu Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu 
1               5                   10                  15      



<210> 10
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> EPO

<400> 10
Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu 
1               5                   10      

<210> 11
<211> 132
<212> PRT
<213> Human immunodeficiency virus type 1 BH10


<220> 
<223> p17

<400> 11
Met Gly Ala Arg Ala Ser Val Leu Ser Gly Gly Glu Leu Asp Arg Trp 
1               5                   10                  15      
Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys Lys Tyr Lys Leu Lys 
            20                  25                  30          
His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Val Asn Pro 
        35                  40                  45              
Gly Leu Leu Glu Thr Ser Glu Gly Cys Arg Gln Ile Leu Gly Gln Leu 
    50                  55                  60                  
Gln Pro Ser Leu Gln Thr Gly Ser Glu Glu Leu Arg Ser Leu Tyr Asn 
65                  70                  75                  80  
Thr Val Ala Thr Leu Tyr Cys Val His Gln Arg Ile Glu Ile Lys Asp 
                85                  90                  95      
Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Ser Lys 
            100                 105                 110         
Lys Lys Ala Gln Gln Ala Ala Ala Asp Thr Gly His Ser Ser Gln Val 
        115                 120                 125             
Ser Gln Asn Tyr 
    130         

<210> 12
<211> 207
<212> PRT
<213> Human immunodeficiency virus type 1 BH10


<220> 
<223> p24

<400> 12
His Gln Ala Leu Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile 
1               5                   10                  15      
Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu 
            20                  25                  30          
Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val 
        35                  40                  45              
Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu 
    50                  55                  60                  
Glu Ala Ala Glu Trp Asp Arg Met His Pro Val Gln Ala Gly Pro Ile 
65                  70                  75                  80  
Pro Pro Gly Gln Ile Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr 
                85                  90                  95      
Thr Ser Thr Leu Gln Glu Gln Ile Thr Trp Met Thr Ser Asn Pro Pro 
            100                 105                 110         
Ile Pro Val Gly Glu Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn 
        115                 120                 125             
Lys Ile Val Arg Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln 
    130                 135                 140                 
Gly Pro Lys Glu Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Arg Val 
145                 150                 155                 160 
Leu Arg Ala Glu Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Glu 
                165                 170                 175     
Thr Leu Leu Val Gln Asn Ala Asn Pro Asp Cys Arg Thr Ile Leu Lys 
            180                 185                 190         
Ala Leu Gly Ser Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys 
        195                 200                 205         

<210> 13
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> None

<400> 13
Ala Ser Arg Glu Leu Glu Arg Phe Leu Leu Glu 
1               5                   10      

<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> None

<400> 14
Ala Ser Arg Glu Leu Glu Arg Phe 
1               5               

<210> 15
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> None

<400> 15
Ala Ala Asn Glu Leu Asp Arg Phe Leu Leu Glu 
1               5                   10      

<210> 16
<211> 8
<212> PRT
<213> Artificial Sequence


<220> 
<223> None

<400> 16
Ala Ala Asn Glu Leu Asp Arg Phe 
1               5               

<210> 17
<211> 16
<212> PRT
<213> Artificial Sequence


<220> 
<223> Peptide gor

<400> 17
Ala Ser Arg Glu Leu Glu Arg Phe Ala Cys Asn Pro Glu Leu Leu Glu 
1               5                   10                  15      



<210> 18
<211> 16
<212> PRT
<213> Artificial Sequence


<220> 
<223> Peptide cpz

<400> 18
Ala Ser Arg Glu Leu Glu Arg Phe Ala Cys Asn Pro Gly Leu Met Glu 
1               5                   10                  15      



